Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




CSF Test Distinguishes Prion Disease from Other Causes of Rapidly Progressive Dementia

By LabMedica International staff writers
Posted on 11 Mar 2025

Rapidly progressive dementias are a category of dementia where patients experience a swift decline from the onset of symptoms to losing functional independence, typically within two years. More...

During the early stages of these dementias, patients often present with nonspecific symptoms that make it difficult to pinpoint a clear diagnosis. However, it is essential to quickly identify the exact cause, as some forms, particularly those caused by autoimmune processes, can be treated, while others cannot. One such form is human prion disease, or Creutzfeldt-Jakob disease (CJD), which is caused by the misfolding of a normal prion protein—an essential protein found in everyone’s body. This misfolding can occur due to genetic mutations that make the protein prone to misfolding, or from spontaneous folding errors. The misfolded protein can then induce other correctly folded prion proteins to adopt the abnormal form, starting a chain reaction. Over time, this process leads to the destruction of neurons. Unfortunately, no cure currently exists for CJD.

Until recently, lab tests for CJD were limited to general markers of neuronal degeneration. These tests could detect the rapid destruction of brain tissue but could not definitively identify the cause. Now, researchers at Mayo Clinic (Rochester, MN, USA) have developed an advanced test that can differentiate prion diseases from other types of rapidly progressive dementias. This new test, conducted using cerebrospinal fluid (CSF), enables quick and accurate diagnoses, which is critical for identifying treatable autoimmune dementias and improving patient care. The RT-QuIC Prion test for CSF can distinguish prion disease from other rapidly progressive dementias, including autoimmune dementias and fast-progressing Alzheimer’s disease. The test provides patients with a clear diagnosis of rapidly progressive dementia faster, thanks to its high sensitivity.

The RT-QuIC (real-time quaking-induced conversion) assay marks the first time clinicians can obtain a specific diagnostic result for prion disease with very high accuracy. Before this test, the cause of the disease could only be conclusively determined after an autopsy. RT-QuIC for prion disease is the only antemortem clinical test of its kind, which does not require a brain biopsy. The RT-QuIC test has been shown to be highly sensitive using CSF samples, which are low-risk and can be handled in a standard clinical laboratory operating at biosafety level 2 (BSL-2). Now, patients with rapidly progressive dementias can receive a definitive diagnosis quickly, with results available in less than a week, a remarkable achievement considering the specialized nature of the RT-QuIC test.

“Basically, you take the patient’s CSF, mix it with a recombinant substrate prion protein that was made in-house at Mayo Clinic, and a fluorescent dye that labels the protein aggregates generated in the reaction,” said Jack Wu, Ph.D., a clinical chemistry fellow who developed and validated the test. “You incubate this plate at a temperature of 55 degrees Celsius while shaking it with certain reagents. It measures for the fluorescence every 45 minutes and does this for 36 hours. The most critical component of this test is the production of high-quality substrate proteins, which sets the basis for the assay’s superior performance in detecting some rare subtypes of human prion diseases.”

Related Links:
Mayo Clinic


New
Gold Member
Collection and Transport System
PurSafe Plus®
Portable Electronic Pipette
Mini 96
New
Sample Transportation System
Tempus1800 Necto
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Pathology

view channel
Image: An adult fibrosarcoma case report has shown the importance of early diagnosis and targeted therapy (Photo courtesy of Sultana and Sailaja/Oncoscience)

Accurate Pathological Analysis Improves Treatment Outcomes for Adult Fibrosarcoma

Adult fibrosarcoma is a rare and highly aggressive malignancy that develops in connective tissue and often affects the limbs, trunk, or head and neck region. Diagnosis is complex because tumors can mimic... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.